Brainstorm Cell Therapeutics Is A Biotechnology Company Dedicated To Developing Autologous Cellular Therapies For Neurodegenerative Diseasesparticularly Amyotrophic Lateral Sclerosisalsand Progressive Multiple Sclerosisms The Company Utilizes A Patient Specific Approachharnessing The Patient S Own Cells To Create Therapies Aimed At Slowing Or Reversing Disease Progression Central To Brainstorm S Efforts Is The Nurownatechnology Platformwhich Involves Harvesting Mesenchymal Stem Cellsmscsfrom Patientsexpanding And Differentiating Them Into Neurotrophic Factor Secreting Cellsand Reintroducing These Cells To Deliver Therapeutic Proteins To Damaged Neural Tissuesthe Platform Has Received Orphan Drug Designation From Both The U Sfda And The European Medicines Agency For Als Treatment Brainstorm Is Actively Engaged In Clinical Developmenthaving Completed A Phase 3 Pivotal Trial For Als And Conducting A Phase 2 Trial For Progressive Msthe Company Collaborates With Organizations Like The California Institute For Regenerative Medicine And The National Ms Society To Support Its Clinical Programs And Aims To Secure Regulatory Approvals For Its Innovative Therapies
